254746-41-3

Upstream product

• 127-08-2 potassium acetate 
• 142031-67-2 methyl 4-bromo-3-(bromomethyl)benzoate 
• 64-19-7 acetic acid 
• 127-09-3 sodium acetate 
• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 

Downstream Products

• 790230-04-5 4-bromo-3-(hydroxymethyl)benzoic acid 
• 254746-40-2 methyl 4-bromo-3-(hydroxymethyl)benzoate 
• 790230-15-8 tert-butyl 4-(isobutylamino)carbonyl-2'-{[3-(methoxycarbonyl)phenyl]amino}carbonyl-4'-[methyl(trifluoroacetyl)amino]biphenyl-2-carboxylate 
• 790230-42-1 tert-butyl 2'-{[3-(aminocarbonyl)phenyl]amino}carbonyl-4-(isobutylamino)carbonyl-4'-(methylamino)biphenyl-2-carboxylate 
• 790230-16-9 2'-(3-carboxy-phenylcarbamoyl)-4-isobutylcarbamoyl-4'-methylamino-biphenyl-2-carboxylic acid tert-butyl ester 
• 790230-14-7 tert-butyl 4'-amino-4-(isobutylamino)carbonyl-2'-({[3-(methoxycarbonyl)phenyl]amino}carbonyl)biphenyl-2-carboxylate 
• 790230-34-1 2'-(3-carbamoyl-phenylcarbamoyl)-4-isobutylcarbamoyl-4'-methyl-biphenyl-2-carboxylic acid methyl ester 
• 790230-10-3 2'-benzyl 2-methyl 4-(isobutylamino)carbonyl-4'-methylbiphenyl-2,2'-dicarboxylate 
• 790230-09-0 2'-formyl-4'-isobutylcarbamoyl-4-methyl-biphenyl-2-carboxylic acid benzyl ester 
• 790230-07-8 {2-formyl-4-[(isobutylamino)carbonyl]penyl}boronic acid 
• 790230-06-7 4-bromo-3-(1,3-dioxolan-2-yl)-N-isobutylbenzamide 
• 790230-05-6 4-bromo-3-hydroxymethyl-N-isobutylbenzamide 

Relevant academic research and scientific papers

OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS

The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.

BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION

The invention provides compounds of formula (I) wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together

BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065

The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1

OXADIAZOLE DIARYL COMPOUNDS

The invention relates to compounds of formula (I): wherein R1, R2, Ra , Rb,Rc and W, have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066

The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.

Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand

Inhibition of tissue factor/factor VIIa complex (TF/FVIIa) is an attractive strategy for antithrombotic therapies. We began with an investigation of a non-amidine TF/FVIIa inhibitor based on a modification of amidine compound 1. Optimization of the substituents on the P1 phenyl portion of the compound 1 led to a neutral or less basic alternative for the 4-amidinophenyl moiety. By further optimization of the substituents on the central phenyl ring, a highly potent and selective TF/FVIIa inhibitor 17d was discovered.